Saved Results

No results saved yet.

Enter a patient name and hit Save on a result.

Clinical calculator summary

EBV-DNA Prognostic Score (NPC)

The integration of pre-treatment plasma Epstein-Barr Virus (EBV) DNA load with TNM staging significantly improves prognostic stratification in Nasopharyngeal Carcinoma (NPC).

Evidence-based context for fast calculator use

Purpose:
EBV-DNA Prognostic Score integrates pre-treatment EBV DNA with TNM staging to stratify nasopharyngeal carcinoma survival and guide therapy.
Population:
patients with nasopharyngeal or head-and-neck cancer in the biomarker and treatment setting described by the model
Factors:
AJCC TNM Stage, Pre-treatment Plasma EBV DNA
Reference:
Lee AW, et al. Validation of the 8th Edition of the AJCC/UICC Staging System for Nasopharyngeal Carcinoma and Evaluation of Proposed Refinements. J Clin Oncol. 2019;37(15):1219-1229.
HomeEBV-DNA Prognostic Score (NPC)
Pin your most used calculators here by clicking the star in the dropdown.

EBV-DNA Prognostic Score (NPC)

Clinical Context & Background

The integration of pre-treatment plasma Epstein-Barr Virus (EBV) DNA load with TNM staging significantly improves prognostic stratification in Nasopharyngeal Carcinoma (NPC). Patients with advanced stage but low EBV DNA often have survival rates comparable to earlier stages, while high EBV DNA identifies a high-risk subgroup requiring intensive therapy.
Primary Source EvidenceLee AW, et al. Validation of the 8th Edition of the AJCC/UICC Staging System for Nasopharyngeal Carcinoma and Evaluation of Proposed Refinements. J Clin Oncol. 2019;37(15):1219-1229.
Formula Logic
Risk stratification based on Stage (I-IV) and EBV DNA cutoff (e.g., 4000 copies/mL).

Reference Data

Risk GroupCriteria3-Year Overall Survival
Very Low RiskStage I> 98%
Low RiskStage II-IVA + Low EBV DNA~ 90%
Intermediate RiskStage II-III + High EBV DNA~ 80%
High RiskStage IVA + High EBV DNA< 70%

Clinical Workflow

Use, Interpret, And Continue The Patient Pathway

Expand for workflow guidance, limitations, examples, and related next steps.

When To Use

  • Use EBV-DNA Prognostic Score (NPC) when eBV-DNA Prognostic Score integrates pre-treatment EBV DNA with TNM staging to stratify nasopharyngeal carcinoma survival and guide therapy.
  • Confirm that the patient, diagnosis, disease phase, and available inputs match the cited model before calculation.

How To Interpret

  • Interpret the displayed result using the calculator-specific formula and reference table, spanning Very Low Risk through High Risk.
  • A boundary result should prompt input verification and clinical review rather than false precision.

What To Do Next

  • Confirm histology, stage, assay method, specimen timing, imaging, treatment phase, and disease-specific guideline.
  • Document the inputs, result, timing, and clinical context so the assessment can be reproduced.

Limitations

  • Biomarker cutoffs depend on assay and timing and should not be transferred without validation.
  • The result supports clinician judgment and does not independently determine treatment.

Validated Population

patients with nasopharyngeal or head-and-neck cancer in the biomarker and treatment setting described by the model

How to apply this result

For a representative case, verify AJCC TNM Stage, Pre-treatment Plasma EBV DNA, calculate the result, and confirm that its classification matches the highlighted reference band before continuing the disease-specific pathway.

Share This Calculator

Share:

Popular Tools

Myeloma Master Panel (R2-ISS & Frailty)Febrile Neutropenia TriagePalliative Survival Prediction

Frequently Asked Questions

When should EBV-DNA Prognostic Score (NPC) be used?

Use it for patients with nasopharyngeal or head-and-neck cancer in the biomarker and treatment setting described by the model when all required inputs and the intended clinical setting are confirmed.

Can EBV-DNA Prognostic Score (NPC) determine treatment by itself?

No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.

Evidence-based oncology decision support. Verify with clinical guidelines.